Neurosense Therapeutics (NRSN) Stock
Clinical stage biotech developing treatments for brain diseases. Here's the price, business snapshot, and what's worth knowing about Neurosense Therapeutics in November 2026.
Neurosense Therapeutics Ltd (NRSN) is a small-cap, clinical-stage biotechnology company focused on developing therapies for neurodegenerative conditions. With a market capitalisation of around $31.18M, the company’s valuation largely reflects progress in research, clinical programmes and any licensing or partnership activity. For investors, key value drivers include clinical trial results, regulatory milestones and strategic collaborations; setbacks can be swift and materially affect the share price. As with many early-stage biotechs, Neurosense is likely to face funding and dilution risk if additional capital is required to advance programmes. Liquidity can be limited and volatility high. This summary is for general educational purposes only and not personalised investment advice — outcomes are uncertain and past performance is not a reliable guide. Investors should review the company’s most recent reports, regulatory filings and seek independent financial or professional advice to assess suitability for their own portfolio and risk tolerance.
Neurosense Therapeutics (NRSN) Stock Forecast
Analyst price target, next 12 months
$7.50
+276.9% vs today's $1.99
Price range over the last 12 months
Close to its 12-month low
Analysts covering Neurosense Therapeutics have a consensus 12-month target of $7.50, above the current price of $1.99.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Neurosense Therapeutics' stock with a target price of $7.5, indicating strong potential for growth.
Financial Health
Neurosense Therapeutics is showing promising cash flow, indicating good operational performance and potential growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Milestones Ahead
Trial results and regulatory updates can move the share price sharply; positive data may attract partners, though outcomes are uncertain.
Scientific Progress Matters
The company’s value depends on translating research into clinical proof; scientific advances are promising but can take years to reach patients.
Small-Cap Dynamics
Market cap near $31.18M means higher volatility and potential liquidity constraints; watch cash position and possible dilution.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
